Table 1.

Study visits of the TEG-BT versus T-BT trial

Time point	Enrolment	Allocation	Post-allocation
	Preoperative	0 d	T0	T1	T2	T3	T4	T5	T6	T7	T8	T9	Discharged
Enrolment
Eligibility screen	X
Informed consent	X
Allocation		X
Interventions
TEG-BT			X	X	X	X
T-BT
Assessments
Demographic data	X	X
Baseline variables		X
HGB		X						X	X	X	X	X
Hct		X						X	X	X	X	X
PLTs		X						X	X	X	X	X
PT		X						X	X	X	X	X
APTT		X						X	X	X	X	X
INR		X						X	X	X	X	X
Fibrinogen		X						X	X	X	X	X
Crystalloid fluid							X
Artificial colloid fluid							X
RBCs							X
FFP							X
PLTs							X
Fibrinogen							X
Prothrombin complex							X
Albumin							X
Blood loss							X
Urine output							X
The amount of blood lost between 0 and 72 hours after surgery											X
Total blood transfusion between 0 and 72 hours after surgery											X
The lowest HGB level											X
ICU duration													X
Overall length of stay													X
Total cost of the hospitalisation													X

T0, entering the operating room; T1, the performance of CRS; T2, before HIPEC; T3, after HIPEC; T4, at the end of surgery; T5, 2 hours after surgery; T6, postoperative day 1; T7, postoperative day 2; T8, postoperative day 3; T9, postoperative day 5.

APTT, activated partial thromboplastin time; FFP, fresh frozen plasma; Hct, haematocrit; HGB, haemoglobin; ICU, intensive care unit; INR, international normalised ratio; PLTs, platelets; PT, prothrombin time; RBCs, red blood cells; T-BT, traditional blood product transfusion; TEG-BT, thromboelastography-guided blood product transfusion.